<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factors to consider as part of shared decision making for RSV vaccination</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factors to consider as part of shared decision making for RSV vaccination</h1>
<div class="graphic"><div class="figure"><div class="ttl">Factors to consider as part of shared decision making for RSV vaccination</div><div class="cntnt"><table cellspacing="0"><colgroup width="30%"></colgroup><colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Questions that patients may have</td> <td class="subtitle1_left">Points that may impact their decision</td> </tr> <tr> <td><strong>Am I at increased risk for infection?</strong></td> <td><strong>The following factors increase the risk of acquiring RSV:</strong> <ul class="decimal_heading"> <li>Residing in a nursing home or other long-term care facility.</li> <li>Having frequent exposure to young children.</li> </ul> </td> </tr> <tr> <td><strong>Am I at increased risk for severe disease if infected?</strong></td> <td><strong>The following conditions increase the risk of developing severe disease (eg, pneumonia, asthma, COPD exacerbation):</strong> <ul class="decimal_heading"> <li>Cardiopulmonary disease (eg, COPD, asthma, CHF, CAD).</li> <li>Kidney disease.</li> <li>Liver disease.</li> <li>Diabetes mellitus.</li> <li>Chronic or progressive neurologic or neuromuscular conditions.</li> <li>Moderate to severe immunocompromise.</li> <li>Hematologic disorders.</li> <li>Frailty.</li> <li>Advanced age.</li> </ul> </td> </tr> <tr> <td><strong>What happens if someone has severe disease?</strong></td> <td><strong>Persons who develop severe disease may require hospitalization, supplemental oxygen, ICU care, or mechanical ventilation:</strong> <ul class="decimal_heading"> <li>RSV leads to approximately 60,000 to 160,000 hospitalizations and 6000 to 10,000 deaths each year among adults 65 years and older.</li> <li>The risk of hospitalization in persons over 65 with underlying conditions can be as high as 16%.</li> <li>Among persons ≥60 years hospitalized with RSV between February 2022 and May 2023, approximately 80% required supplemental oxygen and 24% required ICU care. The risk of mechanical ventilation or death was 13.5%.</li> <li>In persons with severe immunocompromise (eg, selected HCT and lung transplant recipients), mortality rates with RSV can approach 80%.</li> </ul> </td> </tr> <tr> <td><strong>How can the vaccine help me?</strong></td> <td><strong>Vaccination can:</strong> <ul class="decimal_heading"> <li>Reduce the risk of lower tract respiratory disease (eg, cough, wheezing, sputum production, shortness of breath) by 74.5 to 84.4%.</li> <li>Reduce the need to seek medical care for RSV disease by 77.5 to 81.0%.</li> </ul> </td> </tr> <tr> <td><strong>What are the risks of vaccination?</strong></td> <td><strong>Common side effects:</strong> <ul class="decimal_heading"> <li>Mild to moderate injection site reactions.</li> <li>Systemic side effects (eg, fever, fatigue, myalgia) which typically resolve within 4 days.</li> </ul> <p class="extra_spacing_top"><strong>Possible rare side effects:</strong></p> <ul class="decimal_heading"> <li>Neurologic conditions (eg, Guillain-Barré syndrome) have been reported after RSV vaccination in clinical trials, but the association with the vaccine not established.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>Persons 60 years of age and over are eligible to receive one of the available RSV vaccines.</p>
This table reviews factors that may inform a person's decision to be vaccinated. It is based on a shared decision making tool provided by the <a href="https://www.cdc.gov/vaccines/vpd/rsv/downloads/provider-job-aid-for-older-adults-508.pdf" target="_blank">United States Centers for Disease Control</a> and should be used in conjunction with UpToDate content on RSV.</div><div class="graphic_footnotes">CAD: coronary artery disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; HCT: hematopoietic stem cell transplantation; ICU: intensive care unit.</div><div class="graphic_reference">References:
<ol>
<li>Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:793.</li>
<li>Surie D, Yuengling KA, DeCuir J, et al. Disease severity of respiratory syncytial virus compared with COVID-19 and influenza among hospitalized adults aged ≥60 years - IVY Network, 20 U.S. States, February 2022-May 2023. MMWR Morb Mortal Wkly Rep 2023; 72:1083.</li>
<li>Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749.</li>
<li>Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ 2019; 366:l5021.</li>
<li>Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med 2023; 388:595.</li>
<li>Walsh EE, Pérez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023; 388:1465.</li>
</ol></div><div id="graphicVersion">Graphic 143553 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
